pipeline-prospector-insert-v1
X

Find Drugs for Pulmonary/Respiratory Diseases in Preclinical Development in UNITED STATES

A collaboration with SCORR Marketing

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type

            Companies

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): OSP-101

            Therapeutic Area: Pulmonary/Respiratory Diseases

            Highest Development Status: Preclinical Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Altavant Sciences

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Acquisition January 08, 2020

            Details:

            This acquisition expands Altavant’s pipeline to include OSP-101, a novel inhaled interleukin-1 receptor antagonist (IL-1Ra) with orphan drug designation from the U.S. Food and Drug Administration.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): AT-100

            Therapeutic Area: Pulmonary/Respiratory Diseases

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Undisclosed

            Deal Size: $15.5 million Upfront Cash: Undisclosed

            Deal Type: Series C Financing January 08, 2020

            Details:

            This funding will enable clinical development of AT-100 (rhSP-D), while also supporting preclinical research in influenza, respiratory syncytial virus (RSV) and cystic fibrosis.